<DOC>
	<DOCNO>NCT02388048</DOCNO>
	<brief_summary>A clinical study evaluate treatment two drug , name Ofatumumab Ibrutinib , patient lymphoblastic acute leukemia already treated therapy .</brief_summary>
	<brief_title>Ofatumumab &amp; Ibrutinib + Allogeneic Bone Marrow Transplant Consolidation High Risk Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This phase II multicenter , non-comparative , open label study high risk previously treat patient CLL , require therapy , aim evaluate efficacy Ofatumumab Ibrutinib combination .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female , age 18 year 65 year ; 2 . Confirmation BCLL previously treat 1 previous line treatment . 3 . Risk patient CLL define follow : treated patient show 17p deletion &gt; 20 % cell FISH , TP53 mutation , resistant ( SD/PD ) fludarabine contain combination therapy relapse within 12 month fludarabinecontaining combination therapy . 4 . Active disease meeting least 1 follow IWCLL criterion require treatment : Evidence progressive marrow failure manifest development , worsen anemia ( Hb &lt; 10 g/dL ) and/or thrombocytopenia ( platelet &lt; 100,000/mL ) . Massive ( ≥ 6 cm leave costal margin ) , progressive , symptomatic splenomegaly . Massive node ( least 10 cm long diameter ) , progressive symptomatic lymphadenopathy . Progressive lymphocytosis increase 50 % 2month period lymphocyte double time ( LDT ) &lt; 6 month . Autoimmune hemolytic anemia and/or immune thrombocytopenia poorly responsive corticosteroid standard therapy . One diseaserelated symptom : unintentional weight loss &gt; 10 % within 6 month prior screen ; significant fatigue ( inability work perform usual activity ) ; fever &gt; 38.0°C 2 week prior screen ; night sweat 1 month prior screen . 5 . Stage B C CLL accord Binet staging system ; 6 . Stage A disease fit criterion treatment accord IWCLLNCI criterion ( 2008 ) also include . 7. WHO performance status 0II . 8 . Life expectancy ≥ 6 month . 9 . Hematology value must within follow limit : Absolute neutrophil count ( ANC ) ≥ 750/mm3 independent growth factor support ; Platelets ≥100,000/mm3 ≥ 30.000/mm3 bone marrow involvement independent transfusion support either situation . 10 . Biochemical value within follow limit : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x upper limit normal ( ULN ) . Total bilirubin ≤ 1.5 x ULN unless bilirubin rise due Gilbert 's syndrome nonhepatic origin . Serum creatinine ≤ 2 x ULN estimate Glomerular Filtration Rate ( Cockroft Gault ) ≥ 30 mL/min/1.73m2 . 11 . Women childbearing potential men sexually active must practice highly effective method birth control study For female , restriction apply 1 month last dose ibrutinib 12 month last dose Ofatumumab . For male , restriction apply 3 month last dose ibrutinib . Men must agree donate sperm study . 12 . Women childbearing potential must negative serum ( betahuman chorionic gonadotropin [ βhCG ] ) urine pregnancy test Screening . Women pregnant breastfeeding ineligible study . 13 . Sign inform consent document indicate understand purpose procedure require study , include biomarkers , willing participate study . 1 . Major surgery within 3 week registration . 2 . Known central nervous system lymphoma . 3 . History stroke intracranial hemorrhage within 6 month prior registration . 4 . Requires anticoagulation warfarin equivalent vitamin K antagonist ( eg , phenprocoumon ) . 5 . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month Screening , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification . 6 . Vaccinated live , attenuated vaccine within 4 week registration . 7 . Known history human immunodeficiency virus ( HIV ) active Hepatitis C Virus active Hepatitis B Virus infection uncontrolled active systemic infection require intravenous ( IV ) antibiotic . 8 . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk . 9 . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HBDNA test perform positive subject exclude . ***see attached monitoring criterion HBcAb+ HBV DNA negative subject . 10 . Other past current malignancy . Subjects free malignancy least 5 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma eligible . 11 . Requirement treatment strong CYP3A4/5 and/or CYP2D6 inhibitor . 12 . Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease opinion investigator may represent risk patient . 13 . Inability swallow capsule tablet , disease significantly affect gastrointestinal function and/or inhibit small intestine absorption . 14 . Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis . 15 . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenic purpura . 16 . Central nervous system involvement CLL . 17 . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) . 18 . Treatment known nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior enrollment , whichever longer , currently participate interventional clinical study . 19 . Prior treatment antiCD20 monoclonal antibody alemtuzumab within 3 month prior start therapy . 20 . History significant cerebrovascular disease past 6 month ongoing event active symptom sequela . If HBV DNA negative , subject may include must undergo least every 2 month HBV DNA PCR test start treatment treatment course . Prophylactic antiviral therapy may initiate discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>High-risk</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>ibrutinib</keyword>
	<keyword>Lymphoblastic</keyword>
</DOC>